Celgene (CELG) Rating Reiterated by Leerink Swann

Celgene (NASDAQ:CELG)‘s stock had its “buy” rating restated by research analysts at Leerink Swann in a report issued on Friday. They currently have a $120.00 target price on the biopharmaceutical company’s stock. Leerink Swann’s price target would indicate a potential upside of 12.86% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the stock. Morgan Stanley cut shares of Celgene from an “equal weight” rating to an “underweight” rating and set a $120.00 price target for the company. in a report on Thursday, October 5th. BTIG Research restated a “hold” rating on shares of Celgene in a report on Sunday, October 22nd. Cantor Fitzgerald restated a “hold” rating and set a $112.00 price target on shares of Celgene in a report on Monday, October 30th. Vetr upgraded shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 price target for the company in a report on Monday, October 23rd. Finally, Oppenheimer set a $166.00 price target on shares of Celgene and gave the company a “buy” rating in a report on Thursday, November 16th. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $135.17.

Shares of Celgene (NASDAQ CELG) traded down $1.55 during trading hours on Friday, reaching $106.33. 9,611,900 shares of the company were exchanged, compared to its average volume of 4,833,915. The company has a market capitalization of $83,720.00, a PE ratio of 25.08, a PEG ratio of 0.84 and a beta of 1.77. Celgene has a 12-month low of $94.55 and a 12-month high of $147.17. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52.

Celgene (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.87 by $0.04. The firm had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. Celgene’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the prior year, the company posted $1.58 earnings per share. equities analysts anticipate that Celgene will post 6.68 earnings per share for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Neuberger Berman Group LLC boosted its position in shares of Celgene by 4.0% during the first quarter. Neuberger Berman Group LLC now owns 1,844,837 shares of the biopharmaceutical company’s stock worth $229,553,000 after purchasing an additional 71,729 shares in the last quarter. Grisanti Capital Management LLC acquired a new stake in shares of Celgene during the second quarter worth $3,616,000. Lincoln Capital Corp raised its holdings in shares of Celgene by 0.6% during the second quarter. Lincoln Capital Corp now owns 30,580 shares of the biopharmaceutical company’s stock worth $3,971,000 after acquiring an additional 185 shares during the period. RiverPoint Capital Management LLC raised its holdings in shares of Celgene by 3.1% during the second quarter. RiverPoint Capital Management LLC now owns 121,654 shares of the biopharmaceutical company’s stock worth $15,799,000 after acquiring an additional 3,680 shares during the period. Finally, Russell Investments Group Ltd. raised its holdings in shares of Celgene by 9.2% during the second quarter. Russell Investments Group Ltd. now owns 641,697 shares of the biopharmaceutical company’s stock worth $83,344,000 after acquiring an additional 54,210 shares during the period. 79.84% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Celgene (CELG) Rating Reiterated by Leerink Swann” was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://www.com-unik.info/2017/12/25/celgene-celg-rating-reiterated-by-leerink-swann.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit